Introduction {#s1}
============

Biomarkers have assumed a central role in oncology, enabling the detection, characterization, and targeted treatment of a range of cancer types [@pone.0051153-Wistuba1]. The successful application of targeted anticancer therapies depends on the detection of disease subtypes that are most likely to respond to treatment. As such, the detection and validation of tumor biomarkers is critical for the ongoing development of personalized healthcare, both through the support of effective and robust drug trials, and the effective employment of targeted therapies in the clinic [@pone.0051153-Sawyers1].

Biomarkers are classified according to their utility: diagnostic biomarkers are indicators of biological status that allow classification of tumors according to their genetic and/or phenotypic characteristics. Predictive biomarkers allow the response to a particular line of treatment to be anticipated, based on the known mode of action of the chosen therapy and an understanding of the underlying tumor biology. Prognostic biomarkers enable the prediction of disease progression in the absence of treatment, and have been used to identify signaling pathways that are potential drivers of disease, and putative drug targets [@pone.0051153-ODwyer1].

Although techniques such as tissue microarray immunohistochemistry (IHC) and reverse-transcription polymerase chain reaction (RT-PCR) allow high-throughput screening of protein and mRNA biomarkers in clinical samples [@pone.0051153-Denkert1], significant challenges remain. Biomarker levels vary across human populations, and significant heterogeneity may be observed within single cancer types, even within samples from a single tumor [@pone.0051153-Prat1], [@pone.0051153-Jakobsen1]. This is exacerbated by the possibility that first-line chemotherapy may induce DNA damage in tumor cells, leading to changes in biomarker status; as biopsy samples are often obtained before first-line treatment, this may be an obstacle to the correct selection of subsequent targeted therapies, although the extent of this effect remains unclear [@pone.0051153-Jakobsen1].

While some anticancer therapeutics are entering the clinic with companion diagnostic tests, a wider characterization of tumor gene expression and mutation status will enable targeted therapies to be combined for specific patient groups without multiple biopsy procedures. A deeper understanding of different tumor subtypes will help explain mechanisms of drug resistance and open up new channels of therapy and research. For this reason, "biomarker pipelines" play an important role in the development of molecular targeted therapies [@pone.0051153-Weberpals1].

There are additional challenges associated with biomarker identification using clinical samples containing poor-quality or degraded DNA in limited quantities. Most clinical samples are formalin fixed and paraffin embedded (FFPE) for preservation and storage. While enabling samples to be archived for subsequent biomarker identification and comparison with patient outcomes, this method of preservation leads to nucleic acid fragmentation and cross-linking, so only a small proportion of sample DNA can be probed successfully [@pone.0051153-Mittempergher1]. Traditional methods of biomarker detection require 0.5--1 µg high-quality DNA and results may take a significant amount of time to analyze, particularly if samples are to be screened for multiple mutations.

We have developed a high-throughput method for mutation detection (MUT-MAP, mutation multi-analyte panel) based on TaqMan and allele-specific PCR (AS-PCR) assays using a microfluidic chip-based technology. This approach allows the rapid analysis of 71 mutations across a panel of six genes of therapeutic interest. Parallel analysis of 92 clinical trial samples can be carried out using miniscule amounts of DNA (2--100 ng, based on the quality of genomic DNA \[gDNA\] isolated), allowing the simultaneous detection of multiple mutations in a single sample. DNA can be isolated from both fresh frozen and FFPE samples, and the analysis is routinely completed in 2--3 days.

The six-gene panel mutation assay was designed to detect the most common mutations found in *EGFR*, *KRAS*, *PIK3CA*, *NRAS*, *BRAF*, and *AKT1*. Activating mutations in these genes cause aberrant cell signaling and are found in various types of cancer; their encoded proteins are therefore targets for therapeutic inhibition. For example, mutations in *EGFR* are linked with increased activation of the epidermal growth factor receptor (EGFR) signaling pathway, which drives tumor growth and promotes survival in several types of cancer [@pone.0051153-Kuan1]. The *EGFR* and *KRAS* mutation status is predictive of response to anti-EGFR-targeted therapies such as erlotinib, gefitinib [@pone.0051153-Lynch1], and cetuximab [@pone.0051153-Livre1]. Additionally, the BRAF inhibitor vemurafenib is only effective in patients with *V600* mutation-positive melanoma [@pone.0051153-Hatzivassiliou1], [@pone.0051153-Bollag1], and the phosphoinositide-3-kinase (PI3K) inhibitor GDC-0941 is most effective in preclinical tumor models with *PIK3CA* mutations [@pone.0051153-OBrien1].

Although next-generation parallel sequencing holds great promise for mutation detection across the whole genome, these technologies are not yet mature enough for routine, high-throughput analysis of precious clinical samples. Parallel sequencing generally requires larger quantities of DNA for analysis and takes longer to generate data in comparison with our approach. The MUT-MAP microfluidics system provides a readily available platform for the exploratory detection of predictive and prognostic biomarkers in support of current and future personalized healthcare.

Materials and Methods {#s2}
=====================

Overview of the MUT-MAP Microfluidics System {#s2a}
--------------------------------------------

Mutation screening with the MUT-MAP microfluidics system is a multi-stage process. First, DNA is preamplified using custom-designed primer sets for the exons/genes of interest. The BioMark platform (Fluidigm Corp.) is then used to conduct a combination of quantitative PCR (qPCR) mutation detection assays. We employ two assay formats for mutation detection: both formats utilize TaqMan detection of the amplified product [@pone.0051153-Holland1]. In one format, which we refer to as TaqMan genotyping or, simply, TaqMan, the discrimination between mutant and wild-type is driven by a differentially-labeled mutant- and wild-type-specific probe [@pone.0051153-Shi1]. In the other assay format, the discrimination is driven by a mutant-specific primer, or allele-specific PCR (AS-PCR [@pone.0051153-Newton1], [@pone.0051153-Okayama1]). The AS-PCR assays incorporate the use of an engineered Thermus species Z05 DNA polymerase (AS1) and, in some cases, covalently modified primers to enhance the specificity of allele-specific qPCR [@pone.0051153-Will1], [@pone.0051153-Reichert1].

The AS-PCR assays were used for *KRAS* and *EGFR* mutation analysis, and have broader coverage of the predominant mutations in these two genes compared with some commercially available assays. An overview of the protocol and process flow is presented in [figure 1](#pone-0051153-g001){ref-type="fig"}.

![High-Throughput Mutation Detection, Workflow, and Protocol.](pone.0051153.g001){#pone-0051153-g001}

The BioMark protocol involves the introduction of premixed qPCR reagents and preamplified DNA onto the MUT-MAP assay chip via the sample inlets. Assay-specific TaqMan primer/probe mixes are normally added via assay ports. This protocol was modified due to the presence of primers and probes in the qPCR reagents for some reactions (EGFR Mutation Test; Roche Molecular Systems, Inc. \[RMS\]; Pleasanton, CA). To ensure compatibility with the BioMark platform, these samples were introduced via the assay inlets, and both TaqMan and AS-PCR assay reagents were added via the sample inlets on the microfluidic chip. Data analysis was also modified to accommodate these changes.

DNA Preamplification {#s2b}
--------------------

DNA was preamplified in 10 µl reactions on a 96-well plate using a preamplification primer cocktail ([Table S1](#pone.0051153.s001){ref-type="supplementary-material"}) in the presence of 1x ABI PreAmp Master Mix (Applied Biosystems; Foster City, CA). gDNA (2--10 ng) was isolated from cell lines and fresh frozen samples. However,due to the poor quality of DNA obtained from FFPE clinical samples, 50--100 ng was used for preamplification from this source. Primer concentrations were 100 nM during the amplification reaction. Each preamplification sample set included a gDNA control to determine preamplification performance as well as a no-template control. An additional positive control was made in bulk by preamplification of a cocktail of relevant mutant plasmids for all six genes; this control was run on every chip.

Samples were preamplified using a Tetrad Thermal Cycler (BioRad; Hercules, CA) according to the following protocol: 95°C for 10 minutes, then thermal cycling (20 cycles, each of 15 seconds at 95°C followed by 2 minutes at 60°C). Samples were diluted fourfold, mixed, centrifuged at 3500 rpm (5810 R; Eppendorf; Hauppauge, NY), and stored at 4°C or --20°C until further processing. Following preamplification, rigorous procedures were followed to prevent sample contamination, including the use of dedicated workspaces and pipettes for pre- and post-PCR reaction set-up, laminar flow hoods, and personal protective equipment.

Preparation of Reagents {#s2c}
-----------------------

Primer/probe concentrations of 900/200 nM were used in the TaqMan reactions to detect mutations in the *PIK3CA*, *BRAF*, *NRAS*, and *AKT* genes. Custom AS-PCR assays (Roche Molecular Systems) were used to detect mutations in *KRAS* and *EGFR* genes along with custom wild-type assays for both genes. A complete description of primers and probes for the TaqMan reactions is presented in table S2.

A commercially available EGFR Mutation Test (Roche Molecular Systems) was modified to achieve compatibility with the two-color BioMark readout (FAM and VIC) for detection of mutations in *EGFR*. Hexachlorofluorescein (HEX)-labeled probes were spiked into kit mastermixes to detect *S768I* and *T790M* in the VIC channel. Additionally, a custom fourth tube was designed to separately detect exon 20 insertion mutations using MMX3 from the RMS EGFR Mutation Test. The *KRAS* allele-specific assays utilized a research kit from Roche Molecular Systems.

Both TaqMan and AS-PCR assays were carried out using the AS1 qPCR master mix. Rox dye (final concentration 55 nM) for signal normalization and 20x gel electrophoresis sample loading buffer (Fluidigm Corp.) were added to the qPCR reactions.

Assays along with AS1 qPCR master mix were run in duplicate by loading 5 µl into each well of the primed 96.96 Fluidigm Chip. The diluted preamplified DNA samples were mixed with equal volumes of 2x DNA assay loading buffer (Fluidigm Corp.). The samples were run by loading 5 µl into each well on the chip. The chip was then placed in the integrated fluidic circuit controller and loaded before analysis with the BioMark reader. The following thermal cycling protocol was used: 50°C (2 minutes), 70°C (30 minutes), 25°C (10 min), 50°C (2 minutes), and 95°C (4 minutes). This was followed by 40 cycles of 95°C (10 seconds) and 61°C (30 seconds). The initial cycle \[50°C (2 minutes), 70°C (30 minutes), 25°C (10 minutes)\] is part of the protocol recommended by Fluidigm for the 96.96 chip to ensure sufficient mixing of the reagents.

Data were analyzed and cycle threshold (C~T~) values were determined using BioMark real-time PCR analysis software (Fluidigm Corp.), and automated mutation calling was carried out using an algorithm based on the change in C~T~ (ΔC~T~) values between wild-type and mutant or between control and mutant, for TaqMan and AS-PCR assays, respectively.

Six-Gene Mutation Panel {#s2d}
-----------------------

The use of MUT-MAP in this study allowed the screening of 71 mutations across the *EGFR*, *KRAS*, *PIK3CA*, *NRAS*, *BRAF*, and *AKT1* genes. The mutation coverage of this panel is presented in [tables 1](#pone-0051153-t001){ref-type="table"} and [2](#pone-0051153-t002){ref-type="table"}. Validation of mutations detected in clinical samples was performed using commercial mutation detection assays (Qiagen DxS assays for *PIK3CA*, *KRAS*, and *EGFR* mutations), and in-house developed and validated TaqMan assays (for *BRAF*, *NRAS*, and *AKT1*).

10.1371/journal.pone.0051153.t001

###### Mutation Coverage Breakdown by Gene.

![](pone.0051153.t001){#pone-0051153-t001-1}

  Six-Gene Mutation Coverage by TaqMan and Prototype *EGFR* and *KRAS* AS-PCR Assays                                                                                                                                                    
  ------------------------------------------------------------------------------------ ---- ---- ------------------------------------------------------------------------------------------------- ------------------------------------ -----------------
  *EGFR*                                                                                43   18                                                6252                                                             2155 G\>A                     G719S
                                                                                                                                               6253                                                             2155 G\>T                     G719C
                                                                                                                                               6239                                                             2156 G\>C                     G719A
                                                                                             19   See [table 2](#pone-0051153-t002){ref-type="table"} for EGFR exon 19 deletion mutation coverage                                       
                                                                                             20                                                6241                                                             2303 G\>T                     S768I
                                                                                                                                               12376                                                    2307_2308 ins 9(gccagcgtg)       V769_D770insASV
                                                                                                                                               13558                                                2309_2310 complex(ac\>ccagcgtggat)   V769_D770insASV
                                                                                                                                               12378                                                        2310_2311 ins GGT             D770_N771insG
                                                                                                                                               13428                                                    2311_2312 ins 9(gcgtggaca)       D770_N771insSVD
                                                                                                                                               12377                                                        2319_2320 ins CAC             H773_V774insH
                                                                                                                                               6240                                                             2369 C\>T                     T790M
                                                                                             21                                                6224                                                             2573 T\>G                     L858R
                                                                                                                                               12429                                                        2573--2574 TG\>GT                 L858R
                                                                                                                                               6213                                                             2582 T\>A                     L861Q
  *PIK3CA*                                                                              4    9                                                  760                                                             1624 G\>A                     E542K
                                                                                                                                                763                                                             1633 G\>A                     E545K
                                                                                             20                                                 775                                                             3140 A\>G                    H1047L
                                                                                                                                                776                                                             3140 A\>T                    H1047R
  *KRAS*                                                                                18   2                                                  522                                                              35 G\>C                      G12A
                                                                                                                                                516                                                              34 G\>T                      G12C
                                                                                                                                                521                                                              35 G\>A                      G12D
                                                                                                                                                517                                                              34 G\>A                      G12S
                                                                                                                                                518                                                              34 G\>C                      G12R
                                                                                                                                                520                                                              35 G\>T                      G12V
                                                                                                                                                512                                                            34_35 GG\>TT                   G13D
                                                                                                                                                532                                                              38 G\>A                      G12F
                                                                                                                                                533                                                              38 G\>C                      G13A
                                                                                                                                                527                                                              37 G\>T                      G13C
                                                                                                                                                529                                                              37 G\>C                      G13R
                                                                                                                                                528                                                              37 G\>A                      G13S
                                                                                                                                                534                                                              38 G\>T                      G13V
                                                                                             3                                                  554                                                              183 A\>C                     Q61H
                                                                                                                                                555                                                              183 A\>T                     Q61H
                                                                                                                                                549                                                              181 C\>A                     Q61K
                                                                                                                                                553                                                              182 A\>T                     Q61L
                                                                                                                                                552                                                              182 A\>G                     Q61R
  *BRAF*                                                                                1    15                                                 476                                                             1799 T\>A                    p.V600E
  *NRAS*                                                                                4    2                                                  564                                                              38 G\>A                     p.G13D
                                                                                                                                                580                                                              181 C\>A                    p.Q61K
                                                                                             3                                                  584                                                              182 A\>G                    p.Q61R
                                                                                                                                                583                                                              182 A\>T                    p.Q61L
  *AKT1*                                                                                1    4                                                 33765                                                             49 G\>A                     p.E17K

Results {#s3}
=======

Plasmid Validation {#s3a}
------------------

A series of validation experiments was carried out to confirm the reproducibility and accuracy of the microfluidic assay panel. In order to validate the discrimination of closely related sequences by the mutation screening panel, a complete cross-reactivity analysis was conducted by screening every mutant plasmid target against every mutant-specific assay. The C~T~ values were generated by the BioMark real-time PCR analysis software (Fluidigm Corp.) and plotted as shown in [tables 3](#pone-0051153-t003){ref-type="table"}, [4](#pone-0051153-t004){ref-type="table"}, and [5](#pone-0051153-t005){ref-type="table"}. A C~T~ value of 30.0 represents no reactivity, and is indicative of the absence of that allele from the sample. Deviations from this baseline represent assay reactivity, with a lower C~T~ value indicative of increased reactivity. The C~T~ values generated by mutant-specific assays on their corresponding mutant plasmid targets are highlighted in boxed cells ([Tables 3](#pone-0051153-t003){ref-type="table"}, [4](#pone-0051153-t004){ref-type="table"}, and [5](#pone-0051153-t005){ref-type="table"}).

10.1371/journal.pone.0051153.t002

###### Mutation Coverage for EGFR Exon 19 Deletions.
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  *EGFR* Exon 19 Deletion Mutations Covered byPrototype *EGFR* AS-PCR Assays                                    
  ---------------------------------------------------------------------------- ------- ------------------------ ---------------
  30                                                                            26038       2233_2247del15       K745_E749del
                                                                                13550      2235_2248\>AATTC      E746_A750\>IP
                                                                                6223        2235_2249del15       E746_A750del
                                                                                13552      2235_2251\>AATTC      E746_T751\>IP
                                                                                13551       2235_2252\>AAT       E746_T751\>I
                                                                                12385       2235_2255\>AAT       E746_S752\>I
                                                                                12413      2236_2248\>AGAC       E746_A750\>RP
                                                                                6225        2236_2250del15       E746_A750del
                                                                                12728       2236_2253del18       E746_T751del
                                                                                12678       2237_2251del15       E746_T751\>A
                                                                                12386        2237_2252\>T        E746_T751\>V
                                                                                12416      2237_2253\>TTGCT      E746_T751\>VA
                                                                                12367       2237_2254del18       E746_S752\>A
                                                                                12384        2237_2255\>T        E746_S752\>V
                                                                                18427       2237_2257\>TCT       E746_P753\>VS
                                                                                12422       2238_2248\>GC        L747_A750\>P
                                                                                23571       2238_2252del15       L747_T751del
                                                                                12419       2238_2252\>GCA       L747_T751\>Q
                                                                                6220        2238_2255del18       E746_S752\>D
                                                                                6218        2239_2247del9        L747_E749del
                                                                                12382   2239_2248TTAAGAGAAG\>C   L747_A750\>P
                                                                                12383        2239_2251\>C        L747_T751\>P
                                                                                6254        2239_2253del15       L747_T751del
                                                                                6255        2239_2256del18       L747_S752del
                                                                                12403       2239_2256\>CAA       L747_S752\>Q
                                                                                12387       2239_2258\>CA        L747_P753\>Q
                                                                                6210        2240_2251del12       L747_T751\>S
                                                                                12369       2240_2254del15       L747_T751del
                                                                                12370       2240_2257del18       L747_P753\>S
                                                                                13556       2253_2276del24       S752_I759del

10.1371/journal.pone.0051153.t003

###### Cross-Reactivity of *AKT1*, *BRAF*, *PIK3CA*, and *NRAS* Mutants.

![](pone.0051153.t003){#pone-0051153-t003-3}

  Assays             Plasmid controls *AKT1*, *BRAF*, *PIK3CA*, and *NRAS*   Controls                                                                                                                                                                                         
  ----------------- ------------------------------------------------------- ---------- -------------------------------------- ---------- ---------- -------------------------------------- ---------- ---------- ---------- -------------------------------------- ---------- ------
  **RNaseP**                                 30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **11.5**   30.0
  **AKT_WT**                                 30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **15.8**   30.0
  **AKT_E17K**                             **20.0**                            30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                     30.0     30.0
  **Br_WT**                                  30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **13.1**   30.0
  **Br_V600E**                               30.0                            **22.4**                   30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                     30.0     30.0
  **Pk_E542_WT**                             30.0                              30.0                     30.0                     20.6       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **15.5**   30.0
  **Pk_E542K**                               30.0                              30.0                   **16.6**                   30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                     30.0     30.0
  **Pk_E545_WT**                             30.0                              30.0     15.3[a](#nt101){ref-type="table-fn"}     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **12.9**   30.0
  **Pk_E545K**                               30.0                              30.0                     30.0                   **17.2**     30.0                     30.0                     30.0       30.0       30.0                     30.0                     30.0     30.0
  **Pk_H1047_WT**                            30.0                              30.0                     30.0                     30.0       30.0                     20.0                     30.0       30.0       30.0                     30.0                   **12.0**   30.0
  **Pk_H1047R**                              30.0                              30.0                     30.0                     30.0     **15.7**   19.1[a](#nt101){ref-type="table-fn"}     30.0       30.0       30.0                     30.0                     30.0     30.0
  **Pk_H1047_WT**                            30.0                              30.0                     30.0                     30.0       30.0                     26.5                     30.0       30.0       30.0                     30.0                   **12.1**   30.0
  **Pk_H1047L**                              30.0                              30.0                     30.0                     30.0       30.0                   **16.9**                   30.0       30.0       30.0                     30.0                     30.0     30.0
  **Nr_Q61_WT**                              30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **10.5**   30.0
  **Nr_Q61K**                                30.0                              30.0                     30.0                     30.0       30.0                     30.0                   **19.1**     30.0       30.0                     30.0                     30.0     30.0
  **Nr_Q61_WT**                              30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **10.6**   30.0
  **Nr_Q61R**                                30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0     **22.0**     30.0                     30.0                     30.0     30.0
  **Nr_Q61_WT**                              30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                     30.0                   **10.6**   30.0
  **Nr_Q61L**                                30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0     **17.1**                   30.0                     30.0     30.0
  **Nr_G12_WT**                              30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0     16.2[a](#nt101){ref-type="table-fn"}   **10.5**   30.0
  **Nr_G12D**                                30.0                              30.0                     30.0                     30.0       30.0                     30.0                     30.0       30.0       30.0                   **16.7**                   30.0     30.0

Cross-reactions between the assays are unidirectional and hence do not interfere with accurate mutation calls.

10.1371/journal.pone.0051153.t004

###### Cross-Reactivity of *KRAS* Mutants.

![](pone.0051153.t004){#pone-0051153-t004-4}

  Assays                Plasmid Controls *KRAS*          Controls                                                                                                                                                                                                                                                                                                             
  -------------- -------------------------------------- ---------- ---------- -------------------------------------- -------------------------------------- ---------- -------------------------------------- ---------- -------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------
  **Kr_cntrl**                  **12.1**                 **12.2**   **12.1**                 **12.0**                               **12.1**                 **12.4**                 **13.1**                 **12.5**                 **12.6**                 **12.0**   **13.3**   **11.6**   **12.3**   **12.9**   **12.4**   **12.6**   **13.0**   **12.9**   **10.4**   30.0
  **Kr_G12S**                   **14.3**                   24.8       28.0                     28.3                                   26.6                     25.7                     30.0                     25.8                     27.7                     26.1       26.4       25.7       25.8       24.2       24.6       24.7       26.7       27.3       23.9     30.0
  **Kr_G12C**                     24.9                   **14.6**     24.2                     29.4                                   27.9                     29.1     17.6[a](#nt102){ref-type="table-fn"}     26.9                     28.9                     27.9       30.0       30.0       29.6       26.4       28.7       28.9       28.5       30.0       25.6     30.0
  **Kr_G12R**                     28.7                     24.2     **14.2**                   29.8                                   30.0                     28.2                     30.0                     30.0                     28.9                     26.0       30.0       28.2       30.0       28.4       30.0       29.4       29.0       28.3       28.5     30.0
  **Kr_G12D**                     27.6                     28.5       23.8                   **13.6**                                 24.8                     28.1                     30.0                     25.2                     25.2                     24.5       25.3       24.9       25.7       25.0       24.8       25.0       25.9       27.4       22.9     30.0
  **Kr_G12V**                     18.2                     23.4       25.8     13.7[a](#nt102){ref-type="table-fn"}                 **13.8**                   22.7                     20.3                     24.2                     24.3                     24.8       23.5       23.9       22.9       22.6       23.3       23.1       23.8       23.4       21.0     30.0
  **Kr_G12A**                     27.4                     26.2       21.8                     25.0                                   22.8                   **14.1**                   30.0                     28.6                     30.0                     24.8       27.1       28.7       26.9       28.6       28.4       27.6       28.1       29.6       25.3     30.0
  **Kr_G12F**                     30.0                     23.4       30.0                     30.0                                   20.0                     29.3                   **13.1**                   30.0                     30.0                     30.0       30.0       30.0       30.0       28.3       30.0       29.3       30.0       30.0       29.8     30.0
  **Kr_G13S**     15.8[a](#nt102){ref-type="table-fn"}     22.9       22.1                     24.5                                   22.1                     25.0                     26.4                   **13.3**                   23.8                     24.7       24.0       22.7       22.9       23.3       23.0       22.8       24.4       24.2       21.4     30.0
  **Kr_G13C**                     17.3                     24.8       24.7                     22.4                   13.0[a](#nt102){ref-type="table-fn"}     22.0                     24.1                     23.8                   **13.3**                   22.4       23.9       23.7       23.7       22.7       22.4       23.0       23.1       23.1       20.5     30.0
  **Kr_G13R**                     24.9                     26.6       29.9                     27.7                                   23.3                     28.0                     29.8                     25.9                     22.6                   **13.3**     28.0       16.9       26.5       30.0       28.6       30.0       28.5       30.0       26.5     30.0
  **Kr_G13D**                     29.4                     29.0       28.2                     19.9                                   23.7                     23.9                     30.0                     30.0                     29.1                     29.9     **15.0**     25.4       28.1       22.8       22.8       23.3       23.7       23.6       21.4     30.0
  **Kr_G13V**                     25.5                     20.5       26.0                     18.5                                   25.8                     26.8                     28.0                     29.3                     24.8                     30.0       24.3     **12.9**     20.2       26.2       25.9       25.0       26.7       26.1       23.9     30.0
  **Kr_G13A**                     23.6                     22.1       23.4                     17.0                                   20.2                     20.5                     24.7                     21.6     13.9[a](#nt102){ref-type="table-fn"}     20.0       26.7       21.7     **12.9**     21.5       21.3       21.4       22.0       21.9       19.5     30.0
  **Kr_Q61K**                     26.7                     27.8       27.4                     26.6                                   27.3                     26.5                     27.9                     25.5                     27.5                     25.0       29.1       25.2       25.8     **15.9**     30.0       30.0       30.0       30.0       25.3     30.0
  **Kr_Q61L**                     28.2                     28.9       27.3                     26.3                                   28.0                     28.4                     28.3                     26.8                     27.9                     27.1       29.9       26.4       27.4       28.7     **16.5**     28.6       30.0       29.8       25.4     30.0
  **Kr_Q61R**                     26.4                     26.8       26.8                     27.0                                   27.2                     27.4                     26.4                     25.3                     27.3                     25.1       28.3       24.6       25.3       28.5       23.6     **15.4**     27.8       27.0       24.2     30.0
  **Kr_Q61Hc**                    30.0                     30.0       29.5                     29.6                                   30.0                     30.0                     29.6                     29.7                     30.0                     29.3       30.0       29.3       30.0       30.0       30.0       26.6     **17.1**     26.6       27.5     30.0
  **Kr_Q61Ht**                    28.0                     27.4       29.2                     27.1                                   27.0                     29.5                     28.0                     26.2                     28.4                     25.4       29.6       25.6       25.9       26.8       28.4       26.5       28.8     **16.0**     24.8     30.0

Cross-reactions between the assays are unidirectional and hence do not interfere with accurate mutation calls.

10.1371/journal.pone.0051153.t005

###### Cross-Reactivity of *EGFR* Mutants.
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  Assays               Plasmid Controls *EGFR*   Controls                                                                               
  ------------------- ------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------
  **Eg_ex20_Cntrl**             30.0               30.0     **15.2**     30.0     **17.4**     30.0       30.0     **14.1**   **11.8**   30.0
  **Eg_ex28_Cntrl**           **13.0**             30.0       30.0       30.0       30.0       30.0       30.0       30.0     **10.1**   30.0
  **Eg_19del**                  30.0             **13.6**     30.0       30.0       30.0       30.0       30.0       30.0       24.0     30.0
  **Eg_S768I**                  30.0               30.0     **15.0**     30.0       30.0       30.0       30.0       28.9       26.4     30.0
  **Eg_L858R**                  30.0               30.0       30.0     **18.1**     30.0       30.0       30.0       30.0       27.3     30.0
  **Eg_T790M**                  30.0               30.0       24.8       30.0     **17.1**     30.0       30.0       30.0       23.0     30.0
  **Eg_L861Q**                  30.0               30.0       30.0       26.1       30.0     **15.7**     30.0       30.0       23.2     30.0
  **Eg_G719X**                  30.0               30.0       30.0       30.0       30.0       30.0     **18.5**     30.0       26.5     30.0
  **Eg_ins**                    30.0               30.0       30.0       30.0       29.5       30.0       30.0     **13.3**     23.0     30.0

Eg_ex20_Cntrl assay detects exon 20. Hence *EGFR* exon 20 plasmids carrying *S7681*, *T790M*, and insertion mutations are detected.

The C~T~ values and cross-reactivities obtained from the plasmid data were instrumental in generating an automated mutation-calling algorithm to detect the presence or absence of mutations in clinical samples for each of the six genes in the panel. Samples were re-run on multiple chips to validate both intra- and inter-chip reproducibility.

In general, all samples were correctly identified with high reproducibility and no confounding cross-reactivity. Where cross-reactivity did occur, it was generally an easily discriminated partial reaction. For example, in the TaqMan assays, the cross-reactivity observed between alleles such as *PIK3CA E545* wild-type and *E542K* can be attributed to cross-reactivity of probes with highly similar sequences. In the *KRAS* AS-PCR assays, cross-reactivity is likely due to sequence content at the 3′ end of the primer sequences. The unidirectional nature of these cross-reactions made it easy to build an algorithm to classify mutation status.

Validation of Cell Line Samples {#s3b}
-------------------------------

For cell lines and clinical samples, gene-specific custom algorithms were written, taking into account the control C~T~ and the mutant C~T~ values. Samples showing ΔC~T~ \<6 were classified as positive for the specific mutation.

A series of 51 cell lines was screened to detect mutations across the six genes ([Table 6](#pone-0051153-t006){ref-type="table"}). These mutation calls were compared with published characteristics of these cell lines, from the Catalogue of Somatic Mutations in Cancer (COSMIC) [@pone.0051153-Forbes1].

10.1371/journal.pone.0051153.t006

###### Correlation Between Mutation Calls in Cell Lines and Those Reported in the Literature.
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                          Six-Gene Mutation Panel                                                 
  --------- ------------ ------------------------- ----------- ------------ ---------- ---------- -----------------
  1286013      MGH-U3            **E17K**              MND         MND         MND        MND            MND
  905954     SK-MEL-28              MND             **V600E**      MND         MND        MND            MND
  909747       SW1417               MND             **V600E**      MND         MND        MND            MND
  905988     MDA-MB-435             MND             **V600E**      MND         MND        MND            MND
  906844       DU4475               MND             **V600E**      MND         MND        MND            MND
  908125      MEL-JUSO              MND                MND         MND       **Q61L**     MND            MND
  910926        BFTC                MND                MND         MND       **Q61L**     MND            MND
  724831       H1299                MND                MND         MND       **Q61K**     MND            MND
  905955      SKMEL--2              MND                MND         MND       **Q61R**     MND            MND
  909771       THP-1                MND                MND         MND       **G12D**     MND            MND
  1018466      BT483                MND                MND      **E542K**      MND        MND            MND
  905946       MCF-7                MND                MND      **E545K**      MND        MND            MND
  908121     MDA-MB-361             MND                MND      **E545K**      MND        MND            MND
  906851       EFM19                MND                MND      **H1047L**     MND        MND            MND
  905945       T-47D                MND                MND      **H1047R**     MND        MND            MND
  905945       T-47D                MND                MND      **H1047R**     MND        MND            MND
  910948      MFM-223               MND                MND      **H1047R**     MND        MND            MND
  908122     MDA-MB-453             MND                MND      **H1047R**     MND        MND            MND
  909778      UACC-893              MND                MND      **H1047R**     MND        MND            MND
  1479574      LS180                MND                MND      **H1047R**     MND      **G12D**         MND
  905949        A549                MND                MND         MND         MND      **G12S**         MND
  905942      NCI-H23               MND                MND         MND         MND      **G12C**         MND
  910546       PSN-1                MND                MND         MND         MND      **G12R**         MND
  910702       AsPC-1               MND                MND         MND         MND      **G12D**         MND
  908122       SW403                MND                MND         MND         MND      **G12V**         MND
  753624      CAPAN-1               MND                MND         MND         MND      **G12V**         MND
  724873     NCI-H2009              MND                MND         MND         MND      **G12A**         MND
  907790        LoVo                MND                MND         MND         MND      **G13D**         MND
  905960     MDA-MB-231             MND                MND         MND         MND      **G13D**         MND
  907790        LOVO                MND                MND         MND         MND      **G13D**         MND
  687800     NCI-H1650              MND                MND         MND         MND        MND         **19del**
  1028938     HCC4006               MND                MND         MND         MND        MND         **19del**
  1028936      HCC827               MND                MND         MND         MND        MND         **19del**
  1336875       pC9                 MND                MND         MND         MND        MND         **19del**
  924244     NCI-H1975              MND                MND         MND         MND        MND      **L858R/T790M**
  909751        SW48                MND                MND         MND         MND        MND         **G719X**
  905934        PC-3                MND                MND         MND         MND        MND            MND
  910781       AN3 CA               MND                MND         MND         MND        MND            MND
  687804     NCI-H1770              MND                MND         MND         MND        MND            MND
  905947       786-O                MND                MND         MND         MND        MND            MND
  908471     NCI-H1581              MND                MND         MND         MND        MND            MND
  908481     NCI-H2196              MND                MND         MND         MND        MND            MND
  909907      ZR-75-30              MND                MND         MND         MND        MND            MND
  688015     NCI-H2171              MND                MND         MND         MND        MND            MND
  905986       SF-268               MND                MND         MND         MND        MND            MND
  749712      HCC1395               MND                MND         MND         MND        MND            MND
  749714      HCC1937               MND                MND         MND         MND        MND            MND

MND, mutation not detected.

Validation with FFPE Samples {#s3c}
----------------------------

The assay was further validated using clinical FFPE samples harboring known mutations in the genes of interest. A series of 33 FFPE tumor biopsy samples were analyzed by the six-gene mutation panel. Results were compared with data from traditional micro-well plate qPCR assays: mutations in *EGFR*, *KRAS*, and *PIK3CA* were confirmed using Qiagen DxS assays whereas mutations in *BRAF*, *NRAS*, and *AKT1* were validated with custom in-house-validated TaqMan assays. Execution of the experiments was notably faster with the multiplex assay than with the traditional methods. The MUT-MAP system also required only 20--100 ng DNA compared with 0.5--1 µg DNA for traditional assays (Qiagen DxS assays) covering the same set of mutations.

A good correlation was observed between the experimental results and the traditional mutation detection assays ([Table 7](#pone-0051153-t007){ref-type="table"}). Where samples were available, all outputs were in agreement. The discrepant sample HP-45416 (lung) was not tested for the *EGFR T790M* mutation as the Qiagen DxS assays did not carry the *T790M* assay at the time of the study, and retesting is not possible due to lack of additional sample material.

10.1371/journal.pone.0051153.t007

###### Correlation Between Mutation Calls in FFPE Samples and Those Determined by TaqMan/Qiagen DxS Assays.
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  Samples     Tissues   Six-Gene Mutation Panel   TaqMan/Qiagen DxS                                                                                                            
  ---------- --------- ------------------------- ------------------- ------------ ---------- ---------- ----------------- ----- ----------- ------------ ---------- ---------- -----------
  HP-40263      CO                MND                 **V600E**       **H1047R**     MND        MND            MND         MND   **V600E**      \_a         MND        MND         MND
  HP-41677      CO             **E17K**               **V600E**          MND         MND        MND            MND         \_a   **V600E**      MND         MND        MND         MND
  HP-30630      CO                MND                 **V600E**       **E542K**      MND        MND            MND         MND      \_a      **E542K**      MND        MND         MND
  HP-29630      CO                MND                 **V600E**       **E545K**      MND        MND            MND         MND      \_a      **E545K**      MND        MND         MND
  HP-31183      NOS               MND                    MND          **E545K**      MND      **Q61R**         MND         MND      MND      **E545K**      MND        \_a         MND
  HP-32064      NOS               MND                    MND          **H1047R**     MND      **G12D**         MND         MND      MND      **H1047R**     MND      **G12D**      MND
  HP-33002      NOS               MND                    MND          **E545K**      MND      **G12C**         MND         MND      MND      **E545K**      MND      **G12C**      MND
  HP-30760      NOS               MND                    MND          **E545K**      MND      **G12S**         MND         MND      MND      **E545K**      MND      **G12S**      MND
  HP-30626      CO                MND                    MND          **E542K**      MND      **G12V**         MND         MND      MND      **E542K**      MND      **G12V**      MND
  HP-40224      CO                MND                    MND             MND       **Q61R**     MND            MND         MND      MND         MND       **Q61R**     MND         MND
  HP-41675      CO                MND                    MND             MND       **Q61K**     MND            MND         MND      MND         MND       **Q61K**     MND         MND
  HP-40253      CO                MND                    MND             MND         MND      **G12A**         MND         MND      MND         MND         MND      **G12A**      MND
  HP-32864      NOS               MND                    MND             MND         MND      **G12C**         MND         MND      MND         MND         MND      **G12C**      MND
  HP-44508      CO                MND                    MND             MND         MND      **G12D**         MND         MND      MND         MND         MND      **G12D**      MND
  HP-40092      CO                MND                    MND             MND         MND      **G12D**         MND         MND      MND         MND         MND      **G12D**      MND
  HP-30770      NOS               MND                    MND             MND         MND      **G12R**         MND         MND      MND         MND         MND      **G12R**      MND
  HP-41699      CO                MND                    MND             MND         MND      **G12C**         MND         MND      MND         MND         MND      **G12C**      MND
  HP-32201      NOS               MND                    MND             MND         MND      **G12C**         MND         MND      MND         MND         MND      **G12C**      MND
  HP-41676      CO                MND                    MND          **E545K**      MND      **G12S**         MND         MND      MND         \_a         MND      **G12S**      MND
  HP-40264      CO                MND                    MND             MND         MND      **G12S**         MND         MND      MND         MND         MND      **G12S**      MND
  HP-40122      CO                MND                    MND             MND         MND      **G12V**         MND         MND      MND         MND         MND      **G12V**      MND
  HP-41713      CO                MND                    MND             MND         MND      **G12V**         MND         MND      MND         MND         MND      **G12V**      MND
  HP-40249      CO                MND                    MND             MND         MND      **G13D**         MND         MND      MND         MND         MND      **G13D**      MND
  HP-32375      NOS               MND                    MND             MND         MND      **G13D**         MND         MND      MND         MND         MND      **G13D**      MND
  HP-45416      LU                MND                    MND             MND         MND        MND      **L858R/T790M**   MND      MND         MND         MND        MND      **L858R**
  HP-45863      NOS               MND                    MND             MND         MND        MND         **L858R**      MND      MND         MND         MND        MND      **L858R**
  HP-46155      LU                MND                    MND             MND         MND        MND         **19del**      MND      MND         MND         MND        MND      **19del**
  HP-44217      NOS               MND                    MND             MND         MND        MND         **19del**      MND      MND         MND         MND        MND      **19del**
  HP-44217      NOS               MND                    MND             MND         MND        MND         **19del**      MND      MND         MND         MND        MND      **19del**
  HP-46155      LU                MND                    MND             MND         MND        MND         **19del**      MND      MND         MND         MND        MND      **19del**
  HP-29847      CO                MND                    MND          **E545K**      MND      **G12A**         MND         MND      MND      **E545K**      MND      **G12A**      MND
  HP-30384      CO                MND                    MND             MND         MND        MND            MND         MND      MND         MND         MND        MND         MND

MND, mutation not detected.

CO, Adenocarcinoma of Colon.

LU, Adenocarcinoma of Lung.

NOS, Not otherwise specified.

\_a, Insufficient DNA to complete analysis.

Sample Input Titrations {#s3d}
-----------------------

In order to confirm the reproducibility and consistency of the methodology, sample input titrations were carried out. To define the effective DNA input concentration over which the assay could be considered accurate, and identify the wild-type and mutant C~T~ values for each gene, DNA input was varied for plasmids, cell lines, and FFPE samples, with sample preamplification ([Table 8](#pone-0051153-t008){ref-type="table"}). The C~T~ values for both the mutant and wild-type show the expected response to input concentration over the titration range.

10.1371/journal.pone.0051153.t008

###### Sample Input Titrations: Effect on Assay Performance.
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  Plasmid DNA            Mutation Status      Fg Plasmid      Wild-type C~T~       Mutant C~T~    
  ------------------- --------------------- -------------- -------------------- ----------------- -----------
  Plasmid \#1               Pk_E542K             100                30                12.28       
                                                  10                30                15.71       
                                                  1                 30                18.55       
  Plasmid \#2               Pk_E545K             100                30                13.23       
                                                  10                30                16.23       
                                                  1                 30                19.98       
  Plasmid \#3               Pk_H1047R            100                30                11.02       
                                                  10                30                15.33       
                                                  1                 30                19.12       
  Plasmid \#4               Pk_H1047L            100                30                13.63       
                                                  10                30                17.50       
                                                  1                 30                21.37       
  **FFPE DNA**         **Mutation Status**   **DNA (ng)**   **Wild-type C~T~**   **Mutant C~T~**   **ΔC~T~**
  HP-30770                   Kr_G12R             160              10.66               15.87          5.21
                                                  40              12.66               17.88          5.23
                                                  10              14.48               19.99          5.51
  HP-30630                  Pk_E542K             160              14.81               15.21          0.40
                                                  40              16.64               16.68          0.04
                                                  10              18.60               18.93          0.33
  **Cell Line DNA**    **Mutation Status**   **DNA (ng)**   **Wild-type C~T~**   **Mutant C~T~**   **ΔC~T~**
  MGH-U3                     Ak_E17K             120              12.01               11.44          −0.57
                                                  15              15.23               15.17          −0.06

Platform Reproducibility Validation {#s3e}
-----------------------------------

The reproducibility of data from mutation detection assays was also evaluated by the comparison of duplicate experiments. The inter- and intra-chip variability in assay C~T~ values was assessed as shown in [figure 2](#pone-0051153-g002){ref-type="fig"}. A total of 5664 duplicate pairs were mapped on a scatter plot, and the Pearson correlation coefficient (*R* ^2^) was calculated. The *R* ^2^ values were found to be over 0.99 for FAM as well as VIC channels, indicating excellent inter- and intra-chip reproducibility of data generated by the assay.

![Inter- and Intra-Chip Reproducibility Titrations.\
The MUT-MAP panel qPCR assays were run in duplicate and C~T~ outputs were plotted to determine both inter- and intra-chip reproducibility. Data for a typical mutation panel run are shown, with R^2^ correlations of 0.9939 and 0.9909 for inter- and intra-chip reproducibility, respectively.](pone.0051153.g002){#pone-0051153-g002}

Discussion {#s4}
==========

The future of oncology biomarker detection can be delivered by many promising technologies, including multiplexed protein assays, and parallel next-generation genome sequencing [@pone.0051153-Mani1], [@pone.0051153-Cronin1]. The limited maturity of many of these techniques, combined with their timescale and infrastructure demands, means that there is an unmet need for robust high-throughput biomarker detection methods in the clinical drug development setting.

Our validation has demonstrated that MUT-MAP offers a means of detecting a wide range of mutations in a panel of therapeutically relevant genes, enabling the detection of predictive and prognostic biomarkers from very small amounts of sample DNA. A cross-reactivity analysis showed that this platform has the ability to reliably discriminate between closely related mutations. In addition, the ability of the assay to provide robust reproducible data has been validated in both cancer cell lines and FFPE biopsy samples using considerably smaller amounts of sample DNA than traditional assays. Such an approach enables the study of a wide range of oncogenic mutations in precious clinical samples with very little tissue available for analysis.

As mutations previously thought to be unique to particular tumor types have been shown to be present across a range of cancers (Sanger COSMIC database [@pone.0051153-Forbes2]), the six-gene sample panel used here could be applied to multiple clinical and preclinical studies. The parallel detection of multiple mutations in a single sample also supports biomarker development for combination treatment regimens, where previous analyses would have taken place independently. Parallel analysis also removes the need for sample tracking over multiple assays, which arises with traditional screening methods. The process is further optimized for clinical research and clinical trials by the availability of commercial kit components, facilitating adaptation of this technique to select patients for experimental therapeutic regimens based on gene mutation biomarker combinations which are identified using the multiplex approach.

In addition to biomarker mapping in the clinical setting, MUT-MAP will enable the retrospective analysis of stored FFPE samples, allowing additional data to be obtained from previous studies and possibly identifying previously unknown biomarker associations. The AS-PCR component of the assay uses proprietary primer modifications and an enzyme screened for improved mismatch discrimination. This enables the high level of sensitivity demonstrated in our study and allows us to multiplex allele-specific assays. This sensitivity enables the accurate and reliable identification of mutation status in multiple genes, from poor-quality, low-mass, preserved clinical samples, thereby allowing the maximum amount of data to be obtained from each sample, and repeat experiments to be conducted from the same biopsy. This capability has exciting potential for the future study of low-yield exploratory biomarkers such as circulating tumor DNA [@pone.0051153-Sozzi1]. This highly flexible platform can be used to detect mutations beyond the six genes included in this study; in addition, the precise quantification of each amplicon opens up the possibility of being able to detect copy number variations. Most significantly, however, the MUT-MAP assay can form the basis for the development of a platform to support efficient biomarker discovery and validation in support of detection and personalized healthcare.
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